524 related articles for article (PubMed ID: 15117925)
61. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
[TBL] [Abstract][Full Text] [Related]
62. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
[TBL] [Abstract][Full Text] [Related]
63. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
Muratani T; Matsumoto T
Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
[TBL] [Abstract][Full Text] [Related]
64. Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital.
Chung HS; Yong D; Lee M
J Investig Med; 2016 Jun; 64(5):1042-9. PubMed ID: 27101841
[TBL] [Abstract][Full Text] [Related]
65. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
66. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
[TBL] [Abstract][Full Text] [Related]
67. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
68. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
[TBL] [Abstract][Full Text] [Related]
69. Extended-spectrum beta-lactamases.
Turner PJ
Clin Infect Dis; 2005 Aug; 41 Suppl 4():S273-5. PubMed ID: 16032564
[TBL] [Abstract][Full Text] [Related]
70. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control.
Yu WL; Chuang YC; Walther-Rasmussen J
J Microbiol Immunol Infect; 2006 Aug; 39(4):264-77. PubMed ID: 16926972
[TBL] [Abstract][Full Text] [Related]
71. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.
Schwaber MJ; Navon-Venezia S; Schwartz D; Carmeli Y
Antimicrob Agents Chemother; 2005 May; 49(5):2137-9. PubMed ID: 15855548
[TBL] [Abstract][Full Text] [Related]
72. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics.
Sekowska A; Janicka G; Kłyszejko C; Wojda M; Wróblewski M; Szymankiewicz M
Med Sci Monit; 2002 Mar; 8(3):BR100-4. PubMed ID: 11889457
[TBL] [Abstract][Full Text] [Related]
73. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland.
Stefaniuk E; Suchocka U; Bosacka K; Hryniewicz W
Eur J Clin Microbiol Infect Dis; 2016 Aug; 35(8):1363-9. PubMed ID: 27189078
[TBL] [Abstract][Full Text] [Related]
74. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
75. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
76. Prevalence of antimicrobial resistances in common pathogenic Enterobacteriaceae in Australia, 2004: report from the Australian Group on Antimicrobial Resistance.
Pearson J; Turnidge J; Franklin C; Bell J;
Commun Dis Intell Q Rep; 2007 Mar; 31(1):106-12. PubMed ID: 17503650
[TBL] [Abstract][Full Text] [Related]
77. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
Woodford N; Dallow JW; Hill RL; Palepou MF; Pike R; Ward ME; Warner M; Livermore DM
Int J Antimicrob Agents; 2007 Apr; 29(4):456-9. PubMed ID: 17293088
[TBL] [Abstract][Full Text] [Related]
78. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
Livermore DM; Mushtaq S; Warner M; Miossec C; Woodford N
J Antimicrob Chemother; 2008 Nov; 62(5):1053-6. PubMed ID: 18689875
[TBL] [Abstract][Full Text] [Related]
79. Mechanisms of carbapenem resistance among a collection of Enterobacteriaceae clinical isolates in a Texas city.
Bennett JW; Mende K; Herrera ML; Yu X; Lewis JS; Wickes BL; Jorgensen JH; Murray CK
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):445-8. PubMed ID: 20226336
[TBL] [Abstract][Full Text] [Related]
80. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004).
Goossens H; Grabein B
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):257-64. PubMed ID: 16360549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
